The immunohistochemistry for CD34 was examined on the primary tumor tissue sections to determine whether the suppression of primary tumor growth was a result of an antiangiogenic effect (i.e., the inhibition of microvessel formation) of the CXCR4 antagonist. Here, CXCR4 is linked to neoplasm.